ATE346607T1 - Verfahren und zusammensetzungen zur inhibition der angiogenese - Google Patents

Verfahren und zusammensetzungen zur inhibition der angiogenese

Info

Publication number
ATE346607T1
ATE346607T1 AT01968398T AT01968398T ATE346607T1 AT E346607 T1 ATE346607 T1 AT E346607T1 AT 01968398 T AT01968398 T AT 01968398T AT 01968398 T AT01968398 T AT 01968398T AT E346607 T1 ATE346607 T1 AT E346607T1
Authority
AT
Austria
Prior art keywords
methods
compounds
angiogenesis
inhibition
compositions
Prior art date
Application number
AT01968398T
Other languages
English (en)
Inventor
Mahesh C Sharma
George P Tuszynski
Original Assignee
Philadelphia Health & Educatio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health & Educatio filed Critical Philadelphia Health & Educatio
Application granted granted Critical
Publication of ATE346607T1 publication Critical patent/ATE346607T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01968398T 2000-09-01 2001-09-04 Verfahren und zusammensetzungen zur inhibition der angiogenese ATE346607T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22966700P 2000-09-01 2000-09-01
US27720401P 2001-03-20 2001-03-20

Publications (1)

Publication Number Publication Date
ATE346607T1 true ATE346607T1 (de) 2006-12-15

Family

ID=26923501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01968398T ATE346607T1 (de) 2000-09-01 2001-09-04 Verfahren und zusammensetzungen zur inhibition der angiogenese

Country Status (9)

Country Link
EP (1) EP1313504B1 (de)
JP (1) JP2004507482A (de)
AT (1) ATE346607T1 (de)
AU (1) AU2001288648A1 (de)
CA (1) CA2421503A1 (de)
DE (1) DE60124927T2 (de)
DK (1) DK1313504T3 (de)
ES (1) ES2272537T3 (de)
WO (1) WO2002017857A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337548B1 (de) 2000-11-28 2008-07-16 David M. Waisman Antiangiogene polypeptide
CA2514873C (en) 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
WO2005027965A1 (en) * 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
DE102004046540A1 (de) * 2004-09-21 2006-04-06 Eberhard-Karls-Universität Tübingen Universitätsklinikum Annexin-Modulation und Infektionsresistenz
US20060111423A1 (en) * 2004-10-26 2006-05-25 Zeligs Michael A Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
EP3068428B1 (de) 2013-11-13 2022-08-17 Regents of the University of Minnesota Zusammensetzungen mit annexin-ii-variante und verfahren
EP3045470A1 (de) 2015-01-15 2016-07-20 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulatoren der Funktion der Kerndomäne von Annexinen und Verwendungen davon in der Autoimmun- und/oder Krebstherapie
LT3468621T (lt) 2016-06-10 2022-12-27 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Šerdinis aneksinų domenas ir jo panaudojimas antigeno pristatymui ir vakcinavimui

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051364A (en) * 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
EP1064378A2 (de) * 1998-03-27 2001-01-03 The Board Of Trustees Of The Leland Stanford Junior University Durch hypoxie-induzierbare humane gene, proteine und deren verwendung
HUP0103329A3 (en) * 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis

Also Published As

Publication number Publication date
WO2002017857A2 (en) 2002-03-07
EP1313504B1 (de) 2006-11-29
DE60124927D1 (de) 2007-01-11
DE60124927T2 (de) 2007-09-20
JP2004507482A (ja) 2004-03-11
EP1313504A2 (de) 2003-05-28
CA2421503A1 (en) 2002-03-07
DK1313504T3 (da) 2007-02-26
WO2002017857A3 (en) 2002-06-13
EP1313504A4 (de) 2004-06-30
AU2001288648A1 (en) 2002-03-13
ES2272537T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BG101841A (en) Cellular adhesion inhibitors
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
PT1187918E (pt) Antagonistas de tek
NO20003018L (no) Triazinangiogenese-inhibitorer
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
ATE346607T1 (de) Verfahren und zusammensetzungen zur inhibition der angiogenese
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
WO2002018341A3 (en) Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE60214388D1 (de) Verbindungen, bei denen es sich um wirksame inhibitoren des na+/ca2+ austauschmechanismus handelt und die sich zur behandlung von arrhythmien eignen
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313504

Country of ref document: EP

REN Ceased due to non-payment of the annual fee